Is Waldenstrom’s Macroglobulinemia Hereditary?

Waldenström’s macroglobulinemia (WM) is not inherited in a straightforward, single-gene fashion, but it does have a substantial hereditary component. First-degree relatives of someone with WM face roughly a 20-fold increased risk of developing the disease themselves, one of the strongest familial associations seen in blood cancers. The story behind that risk involves a tangle of inherited susceptibility genes, acquired tumor mutations, and shared immune traits within families that researchers are still working to untangle.

How Strong Is the Family Connection?

The clearest evidence for a hereditary element comes from large population studies in Sweden. A study tracking first-degree relatives of WM patients found their risk of developing WM was about 20 times higher than in the general population.¹ That same study found that relatives also had elevated risks for related blood conditions: about a three-fold increase for non-Hodgkin lymphoma, a three-and-a-half-fold increase for chronic lymphocytic leukemia, and a five-fold increase for a precursor condition called MGUS (a generally harmless abnormality in blood proteins that sometimes progresses to cancer).

These numbers are striking, but context helps. WM is rare to begin with, affecting only a few people per million each year. So even a 20-fold increase in risk translates to a small absolute chance for any individual family member. If your baseline lifetime risk is extremely low, multiplying it by 20 still leaves it low. Still, the pattern is clear enough that WM stands out among blood cancers for the strength of its familial clustering.

Family studies have documented every configuration you’d expect if heredity were involved: parent to child (father to son, father to daughter, mother to son, mother to daughter) and between siblings. There is no sex-linked pattern suggesting the trait rides on the X chromosome, and no single dominant or recessive gene has been pinpointed as the cause.

What Runs in Families Beyond WM Itself

Families with WM don’t just share WM. One study of 257 WM patients found that about 19% had at least one first-degree relative with either WM or another B-cell disorder. Among those relatives, the diagnoses were spread across several conditions: non-Hodgkin lymphoma, myeloma, chronic lymphocytic leukemia, MGUS, acute lymphocytic leukemia, and Hodgkin’s disease.² A separate northern Swedish study identified families where WM, MGUS, and myeloma appeared together across generations.³

This pattern suggests what runs in the family isn’t WM specifically but a broader susceptibility to B-cell abnormalities. The inherited predisposition seems to nudge B cells toward going wrong, and the particular form that takes (WM, lymphoma, myeloma, or just a benign MGUS) may depend on which additional hits accumulate over a person’s lifetime.

Autoimmune Conditions and Shared Immune Vulnerability

The hereditary picture extends beyond cancer. Families with WM also show elevated rates of certain autoimmune diseases, and having a family history of specific autoimmune conditions raises your own WM risk. A case-control study found that a family history of Sjögren syndrome was associated with about a five-fold increased risk of WM, while family histories of autoimmune hemolytic anemia and Guillain-Barré syndrome each raised risk by roughly four-fold.⁴

This overlap between autoimmunity and WM in families makes biological sense. Both involve the immune system producing abnormal or excessive responses. The inherited factor may be a broadly dysregulated immune system rather than something specific to cancer, with WM being one possible outcome of that underlying vulnerability.

The Mutations That Drive WM Are Acquired, Not Inherited

Here is where the heredity question gets genuinely confusing, and where people often misunderstand the genetics. The two most important mutations driving WM tumor cells are somatic mutations, meaning they arise during a person’s lifetime and are not passed from parent to child.

The dominant one is a mutation in a gene called MYD88. A landmark study found that over 90% of WM patients carry a specific change in this gene (called L265P) within their tumor cells.⁵ This mutation flips on a signaling pathway that promotes cell survival and growth. Crucially, the same study confirmed that the mutation was absent in normal tissue from the same patients and in healthy donors. It’s an acquired error, not something inherited in the germline.

A second gene, CXCR4, carries activating mutations in up to 40% of WM patients, with over 40 different mutations identified in its coding region.⁶ These CXCR4 mutations lock the receptor into a permanently “on” state, and they too are somatic, found in tumor cells but not inherited through the germline.

So the mutations that actually make WM cells behave like cancer are not hereditary. What seems to be hereditary is a set of background conditions that make those somatic mutations more likely to happen or more likely to lead to disease when they do.

What Is Actually Inherited

If the tumor-driving mutations are acquired, what exactly are families passing down? Research over the past decade points to two layers of inherited risk: common genetic variants that each contribute a small amount of risk, and rarer inherited variants that appear in certain families.

On the common-variant side, genome-wide studies have now identified 11 locations in the genome associated with WM risk. The earliest findings pinpointed two high-risk spots: one near a gene called IRF4 on chromosome 6, which carried a remarkably high risk (people with a specific variant there had about a 21-fold increased risk), and another near TCL1 on chromosome 14, with about a five-fold increase.⁷ An expanded study then identified nine additional risk spots scattered across chromosomes 1, 2, 6, 9, 10, 15, and 16.⁸ Many of these regions sit near genes involved in immune regulation and B-cell biology, which fits with the broader picture of inherited immune susceptibility.

On the rarer-variant side, researchers have examined families with multiple WM cases and found inherited mutations in genes involved in DNA repair and immune surveillance. One study of familial WM pedigrees identified harmful inherited variants in TREX1 and SAMHD1, two genes that work at the intersection of the innate immune response and DNA repair. Additional inherited variants turned up in known cancer-predisposing genes like POT1 and PMS2.⁹ These findings hint that some families may carry inherited defects in the machinery that normally catches and eliminates damaged cells before they become cancerous.

The overall picture is one of polygenic inheritance: many genetic variants, each contributing a piece of risk, adding up to a family’s overall susceptibility.¹⁰ No single inherited gene “causes” WM in the way that BRCA1 mutations cause a large share of hereditary breast cancers. Instead, inherited risk factors set the stage, and acquired mutations like MYD88 L265P provide the final push.

Does Familial WM Behave Differently Than Sporadic Cases?

A natural question for anyone with WM in the family: if you do develop it, does the familial form behave differently? The data here is somewhat reassuring. A large Swedish population-based study compared 245 patients with familial WM (defined as having at least one first-degree relative with WM or a related B-cell cancer) to over 1,000 matched patients with sporadic WM. The familial group was diagnosed notably younger, with a median age of about 67 compared to 72 for sporadic cases. Despite the earlier onset, familial WM patients actually had slightly better overall survival: a median of about 8.7 years compared to 7.0 years for sporadic patients, and this advantage held even after adjusting for age and sex.¹¹

The younger diagnosis likely reflects heightened medical awareness in these families. When your parent or sibling has WM, you and your doctors pay closer attention to early warning signs like unexplained fatigue, elevated blood protein levels, or enlarged lymph nodes. Earlier detection plausibly contributes to the survival difference, though the study couldn’t prove that was the full explanation. It’s also possible that familial WM has subtly different biology, but this hasn’t been confirmed.

Should Families Screen for WM?

Despite the strong familial association, there are currently no formal screening guidelines telling relatives of WM patients to get regular blood work specifically for WM. This isn’t because the risk is dismissed; it’s because WM is slow-growing, often doesn’t require treatment until symptoms appear, and the absolute risk even for relatives remains low. No prospective study has shown that routine screening of asymptomatic family members leads to better outcomes.¹²

That said, many hematologists who treat WM take a practical approach with families. If you have a close relative with WM, it’s reasonable to mention this to your doctor so they can keep it in the back of their mind during routine checkups. Blood tests that happen to show an elevated IgM level or an abnormal protein band would warrant closer follow-up in someone with a family history, even if they might be watched more casually in someone without that history. The key point is awareness, not anxiety: knowing about the family link means you and your doctor can catch things earlier if they develop, without turning your life into a surveillance program for a disease you’ll most likely never get.

Treatment Isn’t Different for Familial Cases

If someone with familial WM does need treatment, the approach is the same as for sporadic cases. There is no evidence that the familial form responds differently to standard therapies, and no data supporting a unique treatment strategy for inherited cases.¹² Both familial and sporadic WM share the same tumor-driving mutations, particularly MYD88 L265P, which is the target of newer treatments like the BTK inhibitor ibrutinib. Because the somatic mutations are the same regardless of how the patient came to develop the disease, the treatments that work against those mutations work for both groups.

This is actually good news. It means that advances in WM therapy, including targeted drugs developed in the last decade, benefit patients with a family history every bit as much as those whose WM appeared out of the blue.

Ethnic and Demographic Variation

WM is considerably more common among people of European descent, and the familial studies that have mapped its hereditary patterns are heavily concentrated in European and especially Scandinavian populations. Population-based data from the United States shows that the disease’s demographics vary by ethnicity: African-American patients tended to be diagnosed at a younger median age (63 years) compared to White patients (73 years), while median overall survival differed as well, with Hispanic patients showing shorter survival and White patients longer survival.¹³

How much of this variation reflects underlying genetic differences versus access to care and diagnostic patterns is an open question. The germline risk loci identified so far were discovered in cohorts of European ancestry, and it remains unclear whether the same variants, or different ones, play a role in other populations. This is a genuine gap in the research. If WM runs in a non-European family, the same general principle applies, that family history matters, but the specific genetic architecture behind the risk may eventually turn out to look different.

Why a Simple “Yes or No” Doesn’t Fit

Asking whether WM is hereditary is a bit like asking whether heart disease is hereditary. The honest answer is that it clearly runs in families, the genetic underpinnings are real and measurable, but no one inherits WM the way you inherit eye color. You inherit a set of risk factors, some common variants that nudge your immune system toward vulnerability and possibly some rarer variants that impair DNA repair or immune surveillance. Whether those risk factors ever produce disease depends on decades of biological events: which somatic mutations happen to arise in your B cells, whether your immune system catches them, and a long list of factors researchers haven’t fully cataloged yet.

The science here is moving quickly. A decade ago, MYD88 L265P hadn’t been discovered, and no germline risk loci had been identified. Now there are 11 confirmed germline risk spots and a growing catalog of rare familial variants. Polygenic risk scores, which combine the effects of many common variants into a single number, are being explored as a way to estimate who among the relatives of WM patients carries the highest inherited risk. These tools aren’t ready for routine clinical use, but they represent the direction the field is heading. For now, the practical takeaway for families is straightforward: if a close relative has WM or a related B-cell condition, make sure your doctor knows. That awareness alone is the most actionable piece of the hereditary puzzle.